MX2019002424A - Composiciones inmunogénicas de consenso sintéticas optimizadas dirigidas al receptor de la hormona estimulante del folículo (fshr). - Google Patents
Composiciones inmunogénicas de consenso sintéticas optimizadas dirigidas al receptor de la hormona estimulante del folículo (fshr).Info
- Publication number
- MX2019002424A MX2019002424A MX2019002424A MX2019002424A MX2019002424A MX 2019002424 A MX2019002424 A MX 2019002424A MX 2019002424 A MX2019002424 A MX 2019002424A MX 2019002424 A MX2019002424 A MX 2019002424A MX 2019002424 A MX2019002424 A MX 2019002424A
- Authority
- MX
- Mexico
- Prior art keywords
- fshr
- stimulating hormone
- hormone receptor
- follicle stimulating
- immunogenic compositions
- Prior art date
Links
- 108010060374 FSH Receptors Proteins 0.000 title abstract 3
- 102000018343 Follicle stimulating hormone receptors Human genes 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 101150105763 FSHR gene Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se provee una composicion inmunogenica que comprende un antigeno de consenso sintetico respecto a la proteina del receptor de hormona estimulante del foliculo (FSHR), la cual es abundante en muchos subtipos de cancer de ovario. En la presente tambien se describe un metodo para tratar una patologia asociada al tumor en un sujeto que lo necesita, mediante la administracion al sujeto de la composicion inmunogenica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662380766P | 2016-08-29 | 2016-08-29 | |
PCT/US2017/049186 WO2018044929A1 (en) | 2016-08-29 | 2017-08-29 | Optimized synthetic consensus immunogenic compositions targeting the follicle stimulating hormone receptor (fshr) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019002424A true MX2019002424A (es) | 2019-08-16 |
Family
ID=61301448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019002424A MX2019002424A (es) | 2016-08-29 | 2017-08-29 | Composiciones inmunogénicas de consenso sintéticas optimizadas dirigidas al receptor de la hormona estimulante del folículo (fshr). |
Country Status (10)
Country | Link |
---|---|
US (2) | US11865166B2 (es) |
EP (1) | EP3503910A1 (es) |
JP (1) | JP2019529383A (es) |
KR (1) | KR20190082195A (es) |
CN (1) | CN110121354A (es) |
AU (1) | AU2017319312A1 (es) |
BR (1) | BR112019004146A2 (es) |
CA (1) | CA3035524A1 (es) |
MX (1) | MX2019002424A (es) |
WO (1) | WO2018044929A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305870B (zh) * | 2019-06-18 | 2020-10-09 | 华南农业大学 | p65基因在卵巢颗粒细胞中调控FGFR1基因的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261800B1 (en) * | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
WO1993020199A1 (en) | 1992-03-30 | 1993-10-14 | Akzo Nobel N.V. | Human gonadotropin receptor (fsh receptor) |
WO2006109696A1 (ja) * | 2005-04-06 | 2006-10-19 | Kyowa Hakko Kogyo Co., Ltd. | 遺伝子組換え卵胞刺激ホルモン組成物 |
GB2527286A (en) * | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
WO2016073456A1 (en) | 2014-11-04 | 2016-05-12 | The Trustees Of The University Of Pennsylvania | Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor |
CN104926945B (zh) * | 2015-05-27 | 2018-03-23 | 江苏省原子医学研究所 | 一种具有fshr靶向性的肿瘤治疗多肽及其应用 |
CN110573173A (zh) * | 2016-09-30 | 2019-12-13 | 宾夕法尼亚大学理事会 | Tert免疫原性组合物及使用其的治疗方法 |
US20210340263A1 (en) * | 2018-08-09 | 2021-11-04 | The Wistar Institute | Anti-Follicule Stimulating Hormone Receptor Antibodies |
-
2017
- 2017-08-29 BR BR112019004146A patent/BR112019004146A2/pt not_active Application Discontinuation
- 2017-08-29 CA CA3035524A patent/CA3035524A1/en not_active Abandoned
- 2017-08-29 MX MX2019002424A patent/MX2019002424A/es unknown
- 2017-08-29 CN CN201780063689.4A patent/CN110121354A/zh active Pending
- 2017-08-29 US US16/328,404 patent/US11865166B2/en active Active
- 2017-08-29 KR KR1020197008999A patent/KR20190082195A/ko not_active Application Discontinuation
- 2017-08-29 EP EP17847392.2A patent/EP3503910A1/en not_active Withdrawn
- 2017-08-29 WO PCT/US2017/049186 patent/WO2018044929A1/en unknown
- 2017-08-29 JP JP2019512278A patent/JP2019529383A/ja active Pending
- 2017-08-29 AU AU2017319312A patent/AU2017319312A1/en not_active Abandoned
-
2023
- 2023-12-15 US US18/541,798 patent/US20240115680A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019004146A2 (pt) | 2019-07-09 |
WO2018044929A1 (en) | 2018-03-08 |
EP3503910A1 (en) | 2019-07-03 |
KR20190082195A (ko) | 2019-07-09 |
US11865166B2 (en) | 2024-01-09 |
CA3035524A1 (en) | 2018-03-08 |
JP2019529383A (ja) | 2019-10-17 |
CN110121354A (zh) | 2019-08-13 |
US20190192644A1 (en) | 2019-06-27 |
US20240115680A1 (en) | 2024-04-11 |
AU2017319312A1 (en) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
CO2017001919A2 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
MX2023014093A (es) | Compuestos que interactuan con glicano y metodos de uso. | |
EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
MX2018016121A (es) | Preparacion de anticuerpos monoclonales marcados con 212pb. | |
MX2019013071A (es) | Metodo de tratamiento inmunoterapeutico de un tumor. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2020006105A (es) | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. | |
MX2017007338A (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis. | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
BR112017004739A2 (pt) | ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
NZ762312A (en) | Anti-pacap antibody | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2019003258A (es) | Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana. | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. |